ARMP
AMEXArmata Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$5.46-2.67 (-32.88%)
2026-05-212026-08-25
News · 26 weeks42-57%
2026-03-012026-08-23
Mix1490d
- SEC Filings9(64%)
- Other3(21%)
- Insider1(7%)
- Earnings1(7%)
Latest news
25 items- SECSEC Form 10-Q filed by Armata Pharmaceuticals Inc.10-Q - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate UpdateLOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2026, and provided a corporate update. "We continue to finalize activities required to initiate a pivotal Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in the second half of 2026," said Dr. Deborah Birx,
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meetingFour AP-SA02 engineering runs completed; clinical trial material production is the next planned manufacturing stepPhase 3 superiority study remains on track to initiate in the second half of 2026LOS ANGELES, July 20, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced significant clinical, regulatory, manufacturing a
- INSIDERChief Executive Officer Birx Deborah covered exercise/tax liability with 14,041 shares, decreasing direct ownership by 7% to 198,417 units (SEC Form 4)4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus BacteremiaFulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patientsLOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the U.S. Food and Drug Administration (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed regulatory framework for the future evaluation o
- SECSEC Form S-8 filed by Armata Pharmaceuticals Inc.S-8 - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECAmendment: Armata Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update8-K/A - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02Supports Phase 3 readiness of AP-SA02Non-dilutive DoD funding totals $28.7M to dateLOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $2.5 million of non-dilutive funding pursuant to a previously announced Department of Defense (DoD) award, received through the Medical Technology Enterprise Consortium (MTEC) and managed by the Naval Medical Research Comman
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECSEC Form 10-Q filed by Armata Pharmaceuticals Inc.10-Q - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate UpdateEntered into secured credit agreement with Innoviva for $25 million maturing in 2029LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2026, and provided a corporate update. "Our top priority in 2026 is advancing Armata's lead Staphy
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical developmentAdvances AP-SA02 on a faster path to potential approval and patient access LOS ANGELES, May 7, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to AP-S
- PRArmata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in Communications Biology, a peer-reviewed journal from Nature Portfolio. The publication, titled, "Structural atlas of Pakpunav
- INSIDERSEC Form 4 filed by Director Gilmer Daniel B.4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gilmer Daniel B.3 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)
- SECSEC Form DEF 14A filed by Armata Pharmaceuticals Inc.DEF 14A - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- SECArmata Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
- PRArmata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of DirectorsLOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Daniel B. Gilmer, Ph.D. has joined the Company's Board of Directors, effective April 24, 2026. Dr. Gilmer has served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer Inc. ("Pfizer") since February 2025. "I am pleased
ARMP FAQ
5 questionsWhat does Armata Pharmaceuticals Inc. do?
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for the treatment of Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing proprietary synthetic phage candidates to target...Where does ARMP stock trade?
Armata Pharmaceuticals Inc. (ARMP) is listed on AMEX.What sector and industry is ARMP in?
Armata Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to ARMP?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare ARMP side-by-side with any of them on Quantisnow.How can I track ARMP on Quantisnow?
Quantisnow aggregates Armata Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARMP to receive live email and push alerts on every new disclosure.